Stock GRI GRI BIO, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

All News GRI Bio, Inc.

Equities

GRI

US3622AW2059

End-of-day quote Nasdaq
Other stock markets
 03:30:00 15/05/2024 am IST 		5-day change 1st Jan Change
0.4007 USD -1.18% Intraday chart for GRI Bio, Inc. +2.72% -85.13%
21/05 GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus CI
20/05 GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis CI

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
GRI Bio, Inc Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus
CI
GRI Bio, Inc. Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis
CI
GRI Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators with Issuance of Korea Patent
CI
GRI Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
GRI Bio, Inc. Receives MHRA Authorization to Conduct Phase 2a Biomarker Study Evaluating GRI-0621 in the United Kingdom
CI
GRI Bio's Board Approves 1-for-7 Reverse Stock Split to Regain Nasdaq Compliance
MT
GRI Bio Announces Reverse Stock Split
AQ
GRI Bio begins patent enrollment for Phase 2a study of GRI-0621 for IPF treatment
AQ
GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
AQ
GRI Bio, Inc. Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for Treatment of Idiopathic Pulmonary Fibrosis
CI
GRI Bio Secures FDA Clearance for Investigational New Drug Application for Pulmonary Fibrosis Treatment
MT
GRI Bio (NASDAQ: GRI) Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
AQ
GRI Bio, Inc. Announces FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant NKT Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis
CI
GRI Bio (NASDAQ: GRI) Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
GRI Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
GRI Bio Presents Data Supporting Innovative Pipeline of NKT Cell Modulators for the Treatment of High-Value Inflammatory, Fibrotic and Autoimmune Diseases
AQ
GRI Bio Presents Translational Data Demonstrating Connection Between NKT Cells and the Pathogenesis of Idiopathic Pulmonary Fibrosis (IPF) at the 2023 Pittsburgh-Ireland International Lung Conference
AQ
GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression
AQ
GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Ask the CEO Conference
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GRI Stock
  4. News GRI Bio, Inc.